Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Week in Review: 2 key recalls impacting cardiology | Cardiac CT's expanded role | LBBB after TAVR
Saturday, May 28, 2022
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

This Week’s News

FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes

The medication failed a routine dissolution test, meaning it could lose its effectiveness. 

READ MORE >
Anagrelide capsules FDA recall Teva Pharmaceuticals USA
Share on Twitter Share on Facebook Share on Linkedin

FDA announces recall of platelet-reducing medication due to risk of clotting or other adverse cardiovascular outcomes

Share on Twitter Share on Facebook Share on Linkedin
Anagrelide capsules FDA recall Teva Pharmaceuticals USA
The medication failed a routine dissolution test, meaning it could lose its effectiveness. 
READ MORE >

VIDEO: The new role of cardiac CT under the 2021 chest pain evaluation guidelines

Eric Williamson, MD, president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, explains the rapid rise of interest in cardiac CT imaging following its inclusion as a top recommendation in the ACC 2021 Chest Pain Evaluation Guidelines.

READ MORE >
Cardiac CT imaging has been moved to the forefront of medical imaging to evaluate chest pain under the new 2021 chest pain guidelines from the AHA and ACC. #Yescct #CCTA #CTA #CT
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: The new role of cardiac CT under the 2021 chest pain evaluation guidelines

Share on Twitter Share on Facebook Share on Linkedin
Cardiac CT imaging has been moved to the forefront of medical imaging to evaluate chest pain under the new 2021 chest pain guidelines from the AHA and ACC. #Yescct #CCTA #CTA #CT
Eric Williamson, MD, president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, explains the rapid rise of interest in cardiac CT imaging following its inclusion as a top recommendation in the ACC 2021 Chest Pain Evaluation Guidelines.
READ MORE >

FDA announces Class I recall of 4,800 imaging catheters due to risk of vascular injury

There have been five reported incidents so far, including one patient injury.

READ MORE >
Dragonfly OpStar Imaging Catheter FDA recall May 2022
Share on Twitter Share on Facebook Share on Linkedin

FDA announces Class I recall of 4,800 imaging catheters due to risk of vascular injury

Share on Twitter Share on Facebook Share on Linkedin
Dragonfly OpStar Imaging Catheter FDA recall May 2022
There have been five reported incidents so far, including one patient injury.
READ MORE >

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

READ MORE >
The FDA has cleared tirzepatide (Mounjaro) from Eli Lilly, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) for improving glycemic control among adults with type 2 diabetes.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves tirzepatide, Eli Lilly’s new type 2 diabetes drug, and the company shares an estimated price

Share on Twitter Share on Facebook Share on Linkedin
The FDA has cleared tirzepatide (Mounjaro) from Eli Lilly, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) for improving glycemic control among adults with type 2 diabetes.
The medication, sold under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.
READ MORE >

Left bundle branch block after TAVR hurts outcomes, even when no permanent pacemaker is required

Researchers tracked data from more than 2,000 TAVR patients, focusing on cardiovascular mortality and hospitalizations for heart failure. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Left bundle branch block after TAVR hurts outcomes, even when no permanent pacemaker is required

Share on Twitter Share on Facebook Share on Linkedin
Researchers tracked data from more than 2,000 TAVR patients, focusing on cardiovascular mortality and hospitalizations for heart failure. 
READ MORE >

TPV valves, CTO PCI and more: SCAI 2022 updates for interventional cardiologists

The first two days of SCAI 2022 were jam-packed with innovative technologies and late-breaking research.

READ MORE >
SCAI 2022 interventional cardiology TAVR CTO PCI TPV cath labs
Share on Twitter Share on Facebook Share on Linkedin

TPV valves, CTO PCI and more: SCAI 2022 updates for interventional cardiologists

Share on Twitter Share on Facebook Share on Linkedin
SCAI 2022 interventional cardiology TAVR CTO PCI TPV cath labs
The first two days of SCAI 2022 were jam-packed with innovative technologies and late-breaking research.
READ MORE >

VIDEO: Contrast media shortage impacting cardiac CT imaging

Eric Williamson, MD, president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, explains how the iodine contrast shortage is causing issues for cardiac CT imaging and ways this can be mitigated.

READ MORE >
Eric Williamson, MD, MSCCT, the president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, explains how the iodine contrast shortage is causing issues for cardiac CT imaging. He discusses ways imagers can stretch they iodine contrast supplies and some technologies that might help conserve contrast. #contrastshortage
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: Contrast media shortage impacting cardiac CT imaging

Share on Twitter Share on Facebook Share on Linkedin
Eric Williamson, MD, MSCCT, the president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, explains how the iodine contrast shortage is causing issues for cardiac CT imaging. He discusses ways imagers can stretch they iodine contrast supplies and some technologies that might help conserve contrast. #contrastshortage
Eric Williamson, MD, president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, explains how the iodine contrast shortage is causing issues for cardiac CT imaging and ways this can be mitigated.
READ MORE >

3D cardiac modeling solution for VT ablation receives FDA clearance

The new software solution was designed with ventricular tachycardia ablation and other cardiac ablation procedures in mind.

READ MORE >
inHEART Medical, an international healthcare company with offices in France and the United States, has received clearance from the U.S. Food and Drug Administration (FDA) for its new 3D visualization software designed to improve the management of ventricular tachycardia (VT) ablation and other cardiac ablation procedures.
Share on Twitter Share on Facebook Share on Linkedin

3D cardiac modeling solution for VT ablation receives FDA clearance

Share on Twitter Share on Facebook Share on Linkedin
inHEART Medical, an international healthcare company with offices in France and the United States, has received clearance from the U.S. Food and Drug Administration (FDA) for its new 3D visualization software designed to improve the management of ventricular tachycardia (VT) ablation and other cardiac ablation procedures.
The new software solution was designed with ventricular tachycardia ablation and other cardiac ablation procedures in mind.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Why new pediatric valve is a breakthrough | FDA's warning after death | Heart surgeon compensation | AI for cardiology questions
Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme